

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 02186)

VOLUNTARY ANNOUNCEMENT

LIPUSU[®] HAS BEEN SUCCESSFULLY RENEWED ITS INCLUSION IN CHINA'S NATIONAL REIMBURSEMENT DRUG LIST (2022 VERSION)

The board of directors (the “**Board**”) of Luye Pharma Group Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Lipusu[®], the Group’s paclitaxel formulation with innovative liposome delivery system, has been successfully renewed its inclusion in category B of China’s National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2022 Version) (“**National Reimbursement Drug List**” or “**NRDL**”) with its original payment standard. All indications of Lipusu[®], including non-small cell lung cancer, ovarian cancer and breast cancer, are all reimbursed under the NRDL.

Lipusu[®] is the Group’s patented paclitaxel formulation with an innovative liposome delivery system and it is a chemotherapy indicated for various cancers such as non-small cell lung cancer, ovarian cancer and breast cancer. As far as the Company is aware, Lipusu[®] is the first paclitaxel liposome product approved for sale in the world and the only paclitaxel liposome product approved for sale in China as at the date of this announcement.

The Board believes that this renewal will ensure that Lipusu[®] can continue to benefit more patients, increase the penetration rate of the product for the related indications, and provide momentum to its long-term growth.

By Order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

Hong Kong, 19 January 2023

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Mr. SUN Xin; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit and Mr. CHOY Sze Chung Jojo.